Medical Oncology

Uzm. Dr. Rıza Umar Gürsu

Doctor and researcher İstanbul Eğitim Araştırma Hastanesi İstanbul
Breast NeoplasmsColorectal NeoplasmsStomach Neoplasms
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Breast Neoplasms 7 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Colorectal Neoplasms 2 publications
  • Stomach Neoplasms 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologysaglik.gov.trFrom source
  • Institutionİstanbul Eğitim Araştırma Hastanesisaglik.gov.trFrom source
  • Area of workBreast NeoplasmsExtracted from 7 publications · Model version —From source
  • Publications46 publicationsOpenAlex, ORCIDFrom source
  • ORCID0000-0002-6331-3632ORCIDFrom source
  • Last synchronised5 November 2026 08:56https://istanbuleah.saglik.gov.tr/TR-1039967/doktorlar.html#riza-umar-gursusaglik.gov.tr

Scientific work

Publications on Breast Neoplasms

46 publications

  1. Clinicopathologic and molecular characteristics of colorectal cancer patients with brain metastases: a multicenter cohort study

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-69206-x Open-access full textSource: OpenAlex

  2. Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study

    Therapeutic Advances in Medical Oncology, 2026

    DOI 10.1177/17588359261430583 PMID 41835339 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  3. Abstract PS5-02-08: Impact of Prior T-DM1 Exposure on the Efficacy of Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer

    Clinical Cancer Research, 2026

    DOI 10.1158/1557-3265.sabcs25-ps5-02-08 Source: OpenAlex

  4. Abstract PS5-05-14: Real-world outcomes of trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study

    Clinical Cancer Research, 2026

    DOI 10.1158/1557-3265.sabcs25-ps5-05-14 Source: OpenAlex

  5. Abstract PS1-11-04: Her2-low expression is associated with inferior progression-free survival in hr-positive metastatic breast cancer treated with CDK4/6 inhibitors

    Clinical Cancer Research, 2026

    DOI 10.1158/1557-3265.sabcs25-ps1-11-04 Source: OpenAlex

  6. Integrated MRI-Derived, Pathologic, and Molecular Biomarkers for Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer

    İstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi, 2026

    DOI 10.38079/igusabder.1975607 Open-access full textSource: ORCID

  7. Cancer-Specific Survival in Octogenarian Breast Cancer Patients: A Competing Risk Analysis of Prognostic Factors

    Current Oncology, 2026

    DOI 10.3390/curroncol33100636 PMID 42930203 Open-access full textSource: OpenAlex

  8. Residual DCIS Versus No Residual Breast Tumor After Neoadjuvant Chemotherapy in ypN0 Breast Cancer: A Retrospective Clinical, MRI, and Survival Comparison

    Cancers, 2026

    DOI 10.3390/cancers18213491 Open-access full textSource: OpenAlex

  9. Association of Pretreatment IronMLR and ANR With Pathological Response Following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

    SSRN Electronic Journal, 2026

    DOI 10.2139/ssrn.7100220 Open-access full textSource: ORCID

  10. Association of Pretreatment ANR and IronMLR With Pathological Response Following Neoadjuvant Chemotherapy in Breast Cancer

    Breast Cancer Targets and Therapy, 2026

    DOI 10.2147/bctt.s623894 PMID 42677318 Open-access full textSource: OpenAlex

View all 46 publications